NCT07100392 - Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab | Biotech Hunter

Enrollment

141

Participants

Timeline

Start Date

August 14, 2025

Primary Completion Date

August 1, 2027

Study Completion Date

August 1, 2028

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG

tauroursodeoxycholic acid (TUDCA)

TUDCA (250 mg, twice daily) will be administered orally until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.

DRUG

Camrelizumab

Camrelizumab will be administered by IV, 200 mg on day 1 of each 14 day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.

DRUG

Regorafenib

Regorafenib 80 mg was given orally once daily on days 1-21 of a 28-day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.

Trial Locations (1)

200032

RECRUITING

Zhongshan Hospital, Fudan University, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER